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Examination of Adduct Formation In Vivo
in the Mouse Between Benzo(a)pyrene
and DNA of Skin and Hemoglobin of
Red Blood Cells
by Lee Shugart* and John Kao*
We are interested in devising techniques which will allow us to measure and quantitate exposure to
chemical carcinogens and which eventually can be used in risk analysis with humans. Our recent research
with HPLC/fluorescence has demonstrated that we can detect, identify, and quantitate the binding of
benzo(a)pyrene (BaP) with DNA of mouse skin. The technique not only allows femtomole amounts of
BaPDE associated with DNA isolated from a single mouse skin to be detected using conventional instru-
mentation, but also establishes the stereochemical origin of the adduct, and has been employed in the
investigation reported here to estimate the concomitant binding of BaP to hemoglobin in vivo.
The temporal existence of BaPDE/DNA adducts in mouse skin over a 5-week period showed that at 35
days after treatment, approximately 15% of the initial adducts were still detectable even though DNA
turnover would predict that they should have been deleted from the genome. The concentration of the
major covalently bound adduct, anti-BaPDE/deoxyguanosine, relative to the total BaPDE/DNA adduct
population remained essentially constant during the 5-week period.
It isknown thattopically applied BaP is absorbed, metabolized, andexcreted bythe mouse. Examination
of hemoglobin of mouse RBCs 24 hr after BaP treatment revealed covalent adduct formation exclusively
via anti-BaPDE. The dose response of adduct binding to hemoglobin and DNA appeared to be similar.
Introduction
Many chemical carcinogens, among them the poly-
cyclic aromatic hydrocarbons, have been shown to bind
covalently to cellular macromolecules after they undergo
metabolic activation (1-3). Furthermore, the tumori-
genic and carcinogenic activities of these compounds,
and in particular benzo(a)pyrene (BaP) have been cor-
related with their ability to form adducts with DNA
(4,5).
We are interested in devising techniques which will
allow us to detect and quantitate exposure to chemical
carcinogens and which eventually can be used in risk
analysis with humans. Our recent research with HPLC/
fluorescence has demonstrated that we candetect, iden-
tify, and quantitate the binding of BaP with DNA of
mouse skin (6-8). The technique not only allows fem-
tomole amounts of BaPDE associated with DNA iso-
lated from a single mouse skin to be detected using
conventional instrumentation, but also establishes the
stereochemical origin of the adduct.
In the investigation reported here we show a corre-
lation between the degree of adduct formation in the
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DNA of the skin and the extent of alkylation of hemo-
globin after exposure of the mouse to BaP.
Methodology
Samplepreparation: BaPinacetone, oracetone alone,
was applied topically to the dorsal skin of C3H mice.
Periodically thereafter, the animals were sacrificed, the
dorsal skin removed, and blood was drawn into hepa-
rinized tubes.
BaP Binding to DNA
The protocol for the estimation of BaP binding to
mouse skin DNA was as follows: (1) proteolytic diges-
tion of the tissue; (2) deproteinization and partitioning
of nucleic acids with chloroform/phenol; (3) enzymatic
depolymerization ofRNA and spermine precipitation of
DNA; (4) BaPDE release from DNA in form of tetrol
by acid hydrolysis; and (5) tetrol resolution by HPLC
and quantitation by fluorescence analysis.
BaP Binding to Hemoglobin
The protocol for the estimation of BaP binding to
hemoglobin of mouse erythrocytes was as follows: (a)SHUGART AND KAO
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FIGURE 1. HPLC/fluorescence proffles oftetrols: (A) release ofacid-
hydrolyzed DNA from skin of mouse that received acetone alone;
(B) acid-hydrolyzed calf thymus DNA treated in vitro with au-
thentic anti- and syn-diol epoxides of BaP; (C) acid-hydrolyzed
DNA from dorsal skin ofmouse exposed to 200 ,ug BaP in acetone.
recovery of RBCs and lysis with water; (2) removal of
cell debris; (3) isolation of globin by precipitation with
acetone/5mM HCI where noted; (4) and (5) as in the
DNA protocol.
Results
BaPDE-DNA Adducts
Figure 1 shows typical fluorescence profiles obtained
by HPLC/ODS chromatography for various materials
tested. Figure 1A is the fluorescence proffle of acid-
hydrolyzed DNA from dorsal skin of a mouse that had
acetone topically applied. No fluorescent peaks indica-
tive of tetrols are observed. Figure 1B is the profile
derived fromthehydrolysis ofcalfthymus DNAtreated
in vitro with authentic anti- and syn-diol epoxides of
BaP. Figure 1C is the profile of acid-hydrolyzed DNA
obtained from the dorsal skin of a mouse exposed to
BaP for 24 hr.
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FIGURE 2. Time course ofanti-BaPDE binding (or tetrol I-1) to skin
ofC3H (0) male or (O) female mouse. Mice were treated topically
with 200 ,ug of BaP in acetone and DNA isolated at various times
from 1 to 35 days after treatment.
guanosine adduct with respect to the total BaPDE-
DNA adduct population over the time span shown in
Figure 2.
BaP Binding to DNA and Hemoglobin
Figure 3 is the HPLC/fluorescence profiles oftetrols
which were acid-released (A) from mouse skin 24 hr
after exposure to a single topical dose of BaP, and (B)
from hemoglobin isolated from RBCs of the same
mouse. These data show that BaP forms adducts not
only with the DNA in the target tissue, but also con-
comitantly with the hemoglobin. The absence oftetrols
II-1 and II-2inthe HPLC/fluorescence chromatography
of hemoglobin indicates that adduct formation in the
RBC is almost exclusively via the anti-BaPDE meta-
bolite of BaP.
Persistence of Anti-BaPDE-DNA Adducts
The temporal existence of BaPDE-DNA adducts in
C3H mouse skin is illustrated in Figure 2. Thirty days
after a single application of BaP, a marked decrease in
adducts has occurred. A small percentage of the total
population of adducts continue to persist after 4 weeks
with ahalf-life approaching30days. Thefraction ofanti-
BaPDE-deoxyguanosine adducts, whichrepresents the
major covalently bound deoxynucleoside (3) present in
the total population of anti-BaPDE-DNA adducts was
determined. The data obtained indicate no preferential
removal or persistence of the anti BaPDE-deoxy-
Globin as Target Molecule in RBCs
Thatglobin is the molecule in the RBCs where adduct
formation occurs is inferred from the following obser-
vations. Upon lysis of the RBCs, no BaP binding is
found in the cell debris. The degree ofbinding found in
the recovered hemoglobin does not change upon ex-
traction of ethyl acetate, indicating that the tetrols re-
leasedbyacidhydrolysis are fromcovalentlybound BaP
metabolites. Furthermore, globin isolated by treating
the hemoglobin with acetone/5 mM HCI at -20°C still
contains BaP adducts which are unaffected by subse-
quent treatment with RNase and DNase, but which
become labile to proteolytic activities.
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FIGURE 3. HPLC/fluorescence profiles oftetrols: (A) liberated from
DNA isolated from female, C3H mouse skin 24 hr after exposure
to a single topical dose of 300 ,ug BaP; (B) liberated from hemo-
globin isolated from RBCs of same mouse.
Similarity between Adduct Formation with
DNA and Hemoglobin
The amount of adduct formation in both DNA and
hemoglobin was determined in a group of mice 24 hr
after being exposed topically to various concentrations
of BaP. The data are plotted as the log of BaP binding
observed versus the log dose of BaP applied (Fig. 4).
The striking feature of these data is the apparent par-
allelism of the two curves.
Discussion
It is known that topically applied carcinogens, such
as PAHs, are absorbed, metabolized, and excreted by
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FIGURE 4. Log-log plot relating BaP binding versus the dose of
BaP applied to mouse skin: (0) BaP binding of hemoglobin ex-
pressed as pg tetrol I-1/mg hemoglobin; (@) BaP binding to DNA
expressed as ng tetrol I-1/g DNA. Each data point represents the
average values from two mice.
the mouse (9,10). In the cells of the skin at the site of
application and where subsequent tumor formation oc-
curs, metabolites ofPAHs are converted toelectrophilic
agents which react with nucleophilic centers in nucleic
acids and proteins (1-3). A good correlation has been
demonstrated between the amount ofBaP bound to the
DNA of mouse skin and its carcinogenic activity (4,5).
In fact, the ultimate carcinogenic form is thought to be
the BaP-metabolite, anti-BaPDE, and it has been pro-
posed that the quantitation of adduct formation of this
compound with DNA be used as a measure of the "bi-
ologically effective" dose for BaP carcinogenicity (11,12).
We have shown a correlation between the degree of
adduct formation in the target organ and the extent of
alkylation of hemoglobin with benzo(a)pyrene, a clas-
sical PAH.
The suitability of hemoglobin as a cellular molecule
for estimating carcinogenic risk of BaP exposure (and
possibly PAHs) is suggested by the data presented here.
First, the interaction of BaP with hemoglobin is highly
specific, and occurs, presumably, via anti-BaPDE, the
same ultimate carcinogenic form ofBaP which interacts
with DNA in the target tissue; second, the dose re-
sponse of anti-BaPDE binding to hemoglobin appears
similar to that of DNA, thus reflecting the "in vivo"
carcinogenic dose ofBaP; third, the adduct, once formed,
is easy to measure; and fourth, hemoglobin is readily
available.
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